Streetbeat News

LGST

Semper Paratus Acquisition Corp

Open

4.74

Mkt cap

67M

Volume

12K

High

5.40

P/E Ratio

50.11

52-wk high

11.50

Low

4.51

Div yield

N/A

52-wk low

4.08

Tevogen Bio Holdings Inc. has completed a business combination with Semper Paratus Acquisition Corporation and will be listed on Nasdaq under the ticker 'TVGN'. This move is expected to increase Tevogen's access to capital, accelerating the development of its off-the-shelf T cell therapy products for virology, oncology, and neurology. The company's innovative platform aims to address unmet needs in large patient populations with a focus on affordability and advanced science.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 8:56 pm

Semper Paratus Acquisition has officially approved a merger with Tevogen Bio, marking a significant move in the biotech industry. This strategic merger aims to leverage Semper Paratus's financial and strategic resources with Tevogen Bio's expertise in developing innovative treatments. The merger is expected to enhance the combined entity's capabilities in bringing advanced therapeutic solutions to the market.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 1:43 pm

Semper Paratus Acquisition Corporation (NASDAQ:LGST, LGSTW) has filed a Prospectus Supplement to its definitive proxy statement/prospectus for an extraordinary general meeting to vote on a Business Combination with Tevogen Bio Inc. The merger will result in Semper Paratus de-registering from the Cayman Islands, redomesticating to Delaware, and renaming to Tevogen Bio Holdings Inc. The combined entity plans to list its common stock and public warrants on Nasdaq instead of NYSE American.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 9:30 pm

Tevogen Bio and Semper Paratus Acquisition Corporation have announced the effectiveness of their registration statement by the SEC for their business combination. The pro forma equity value of Tevogen Bio's portion is expected to be $1.2 billion. Tevogen Bio is a biotech company specializing in T cell therapeutics for virology, oncology, and neurology.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:59 pm

Semper Paratus Acquisition Corporation has regained compliance with certain Nasdaq listing requirements.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:55 pm

Tevogen Bio Inc. is set to become publicly listed on the NYSE through a business combination with Semper Paratus Acquisition Corporation. The transaction is expected to provide Tevogen Bio with access to capital markets and accelerate the development of its product, TVGN 489, a COVID-19 therapeutic solution. The combined company will be named Tevogen Bio Holdings Inc. and is expected to be listed on the NYSE under the ticker symbol 'TVGN'. The pro forma equity value of the combined company is expected to be approximately $1.2 billion, with the merger expected to be completed in Q4 2023.

Portfolio Pulse from Happy Mohamed

June 29, 2023 | 12:09 pm

Shares of Semper Paratus Acquisition Corp have been halted due to pending news. The nature of the news is not yet disclosed.

Portfolio Pulse from Happy Mohamed

June 29, 2023 | 12:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.